Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPEG in Beta Thalassemia (β-NTDT)
NCT02950857Phase 1Completed
- Sponsor
- Prolong Pharmaceuticals
- Start
- Jun 2017
- Primary completion
- Sep 2017
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of methoxy polyethylene glycol-epoetin beta in beta thalassemia (3 arms), sponsored by Prolong Pharmaceuticals. Primary endpoint: Number of participants with abnormal laboratory values and/or adverse events related to treatment at 60 days. Started Jun 2017; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT02950857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950857.